Osteoclast differentiation in rheumatoid arthritis

References

• Yokota K, Miyazaki T, Hemmatazad H, et al. The pattern-recognition receptor nucleotide-binding oligomerization domain-containing protein 1 promotes production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2012;64(5):1329–1337. doi: 10.1002/art.34318.
   PubMedGoogle Scholar
• Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628–639. doi: 10.1056/NEJMra1909094.
   PubMed Web of Science ®Google Scholar
• Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17–33. doi: 10.1038/s41584-020-00541-7.
   PubMed Web of Science ®Google Scholar
• Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20–33. doi: 10.1136/annrheumdis-2021-220973.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18(7):415–429. doi: 10.1038/s41584-022-00793-5.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638–649. doi: 10.1038/nrg1122.
   PubMed Web of Science ®Google Scholar
• Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231–1234. doi: 10.1038/nm.2452.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889–901. doi: 10.1016/s1534-5807(02)00369-6.
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Nakashima T, et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med. 2006;12(12):1410–1416. doi: 10.1038/nm1515.
   PubMed Web of Science ®Google Scholar
• Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202(9):1261–1269. doi: 10.1084/jem.20051150.
   PubMed Web of Science ®Google Scholar
• Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev. 2009;231(1):241–256. doi: 10.1111/j.1600-065X.2009.00821.x.
   PubMed Web of Science ®Google Scholar
• Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001;159(5):1689–1699. doi: 10.1016/S0002-9440(10)63016-7.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Ishiguro N, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 2016;75(6):983–990. doi: 10.1136/annrheumdis-2015-208052.
   PubMed Web of Science ®Google Scholar
• Jung YK, Kang YM, Han S. Osteoclasts in the inflammatory arthritis: implications for pathologic osteolysis. Immune Netw. 2019;19(1):e2. doi: 10.4110/in.2019.19.e2.
   PubMed Web of Science ®Google Scholar
• O'Brien W, Fissel BM, Maeda Y, et al. RANK-independent osteoclast formation and bone erosion in inflammatory arthritis. Arthritis Rheumatol. 2016;68(12):2889–2900. doi: 10.1002/art.39837.
   PubMed Web of Science ®Google Scholar
• Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106(12):1481–1488. doi: 10.1172/JCI11176.
   PubMed Web of Science ®Google Scholar
• Axmann R, Böhm C, Krönke G, et al. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum. 2009;60(9):2747–2756. doi: 10.1002/art.24781.
   PubMedGoogle Scholar
• Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed Sub-analysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52(4):1020–1030. doi: 10.1002/art.20982.
   PubMedGoogle Scholar
• Smolen JS, Avila JCM, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71(5):687–693. doi: 10.1136/annrheumdis-2011-200395.
   PubMed Web of Science ®Google Scholar
• Yokota K, Sato K, Miyazaki T, et al. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol. 2014;66(1):121–129. doi: 10.1002/art.38218.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Kikuta J, Sudo T, et al. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol. 2019;20(12):1631–1643. doi: 10.1038/s41590-019-0526-7.
   PubMed Web of Science ®Google Scholar
• Yokota K, Sato K, Miyazaki T, et al. Characterization and function of tumor necrosis factor alpha and interleukin-6-Induced osteoclasts in rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1145–1154. doi: 10.1002/art.41666.
   PubMed Web of Science ®Google Scholar
• Andreev D, Kachler K, Schett G, et al. Rheumatoid arthritis and osteoimmunology: the adverse impact of a deregulated immune system on bone metabolism. Bone. 2022;162:116468. doi: 10.1016/j.bone.2022.116468.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Kawakami A. The monocyte-to-osteoclast transition in rheumatoid arthritis: recent findings. Front Immunol. 2022;13:998554. doi: 10.3389/fimmu.2022.998554.
   PubMedGoogle Scholar
• Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454–1462. doi: 10.1136/annrheumdis-2019-215764.
   PubMed Web of Science ®Google Scholar
• Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80(7):848–858. doi: 10.1136/annrheumdis-2020-219214.
   PubMed Web of Science ®Google Scholar